Advertisement

CNS Drugs

, Volume 16, Issue 3, pp 165–174 | Cite as

Drug-Induced Pisa Syndrome (Pleurothotonus)

Epidemiology and Management
  • Toshihito Suzuki
  • Hisashi Matsuzaka
Therapy in Practice

Abstract

Long-term administration of antipsychotics occasionally produces persistent dystonia of the trunk, a disorder known as Pisa syndrome (or pleurothotonus). The development of Pisa syndrome is most commonly associated with prolonged treatment with antipsychotics; however, it has also been reported, although less frequently, in patients who are receiving other medications (such as cholinesterase inhibitors and antiemetics), in those not receiving medication (idiopathic Pisa syndrome) and in those with neurodegenerative disorders.

Drug-induced Pisa syndrome predominantly develops in females and in older patients with organic brain changes. It sometimes occurs after the addition of another antipsychotic to an established regimen of antipsychotics or insidiously arises in antipsychotic-treated patients for no apparent reason. The condition generally disappears after antipsychotic drugs are discontinued. Although a pharmacological therapy for drug-induced Pisa syndrome has not been established, we have reported that anticholinergic drugs are effective in about 40% of patients who have episodes of Pisa syndrome with the remaining patients responding to the withdrawal or reduction of daily doses of antipsychotic drugs.

The characteristics of its development and prognosis indicate that druginduced Pisa syndrome consists of two types of dystonia. Some patients develop clinical features of acute dystonia, whereas others develop symptoms similar to tardive dystonia. Like that of tardive dystonia, Pisa syndrome responds better than tardive dyskinesia to a relatively high daily dose of an anticholinergic. However, the significant improvement caused by the withdrawal of antipsychotic drugs in Pisa syndrome differentiates it from tardive dystonia. Thus, Pisa syndrome including these features is considered to be an atypical type of tardive dystonia.

These clinical characteristics suggest that the underlying pathophysiology of drug-induced Pisa syndrome is complex. A dopaminergic-cholinergic imbalance, or serotonergic or noradrenergic dysfunction, may be implicated. Asymmetric brain functions or neural transmission may also be considered as underlying mechanisms of the development of Pisa syndrome that is resistant to anticholinergic drugs.

Idiopathic Pisa syndrome is characterised by an adult-onset, segmental truncal dystonia in patients with no previous exposure to antipsychotics. It occurs rarely but shows a complete resolution with high doses of anticholinergic drugs.

Keywords

Clozapine Dystonia Antipsychotic Drug Tardive Dyskinesia Extrapyramidal Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054–60PubMedCrossRefGoogle Scholar
  2. 2.
    Keegan DL, Rajput AH. Drag induced dystonia tarda: treatment with L-dopa. Dis Nerv Syst 1973; 34: 167–9PubMedGoogle Scholar
  3. 3.
    Fahn S, Jankovic J. Practical management of dystonia. Neurol Clin 1984; 2: 555–69PubMedGoogle Scholar
  4. 4.
    Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drags. Neurology 1982; 32: 1335–46PubMedCrossRefGoogle Scholar
  5. 5.
    Jeste DV, Wisniewski AA, Wyatt RJ. Neuroleptic-associated tardive syndromes. Psychiatr Clin North Am 1986; 9: 183–92PubMedGoogle Scholar
  6. 6.
    Ekbom K, Lindholm H, Ljungberg L. New dystonic syndrome associated with butyrophenone therapy. Z Neurol 1972; 202: 94–103PubMedCrossRefGoogle Scholar
  7. 7.
    Yassa R. The Pisa syndrome: a report of two cases. Br J Psychiatry 1985; 146: 93–5PubMedCrossRefGoogle Scholar
  8. 8.
    Saxena S. Tardive dystonia and Pisa syndrome [letter]. Br J Psychiatry 1986; 149: 524PubMedCrossRefGoogle Scholar
  9. 9.
    Guy N, Raps A, Assael M. The Pisa syndrome during maintenance antipsychotic therapy [letter]. Am J Psychiatry 1986; 143: 1492PubMedGoogle Scholar
  10. 10.
    Pilette WL. Pisa syndrome, or pleurothotonus. Am J Psychiatry 1987; 144: 969–70PubMedGoogle Scholar
  11. 11.
    Amore M, Cerisoli M, Campanile S, et al. Pisa syndrome: report of a case. Ital J Neurol Sci 1988; 9: 273–4PubMedCrossRefGoogle Scholar
  12. 12.
    Davidson M, Powchik P, Davis KL. Pisa syndrome in Alzheimer’s disease [letter]. Biol Psychiatry 1988; 23: 213PubMedCrossRefGoogle Scholar
  13. 13.
    Remington GJ. The Pisa syndrome: possible role for serotonin and noradrenaline. J Clin Psychopharmacol 1988; 8: 228–9PubMedCrossRefGoogle Scholar
  14. 14.
    Chiu HFK, Li SW, Lee S. Pisa syndrome in a Chinese patient. Aust N Z J Psychiatry 1989; 23: 127–8PubMedCrossRefGoogle Scholar
  15. 15.
    Suzuki T, Koizumi J, Moroji T, et al. Clinical characteristics of the Pisa syndrome. Acta Psychiatr Scand 1990; 82: 454–7PubMedCrossRefGoogle Scholar
  16. 16.
    Turk J, Lask B. Pisa syndrome in an adolescent on neuroleptic medication. Br J Psychiatry 1991; 158: 422–3PubMedCrossRefGoogle Scholar
  17. 17.
    Suzuki E, Kanba S, Nibuya M, et al. Use of pimozide in the Pisa syndrome. Am J Psychiatry 1992; 149: 1114–5PubMedGoogle Scholar
  18. 18.
    Fichtner CG, Pechter BM, Jobe TH. Pisa syndrome mistaken for conversion in an adolescent. Br J Psychiatry 1992; 161: 849–52PubMedCrossRefGoogle Scholar
  19. 19.
    Garcia C. Pisa-syndrom. Nervenarzt 1992; 63: 434–9PubMedGoogle Scholar
  20. 20.
    Kurtz G, Kapfhammer HP, Peuker B. Pisa-syndrome unter clozapintherapie. Nervenarzt 1993; 64: 742–6PubMedGoogle Scholar
  21. 21.
    Suzuki T, Kurita H, Hori T, et al. The Pisa syndrome (pleurothotonus) during antidepressant therapy. Biol Psychiatry 1997; 41: 234–6PubMedCrossRefGoogle Scholar
  22. 22.
    Diez-Martin JM. The Pisa syndrome as another acute dystonia subtype. J Drug Dev Clin Pract 1995; 7: 59–61Google Scholar
  23. 23.
    Padberg F, Stubner S, Buch K, et al. Pisa syndrome during treatment with sertindole. Br J Psychiatry 1998; 173: 351–2PubMedCrossRefGoogle Scholar
  24. 24.
    Bruneau MA, Stip E. Metronome or alternating Pisa syndrome: a form of tardive dystonia under clozapine treatment. Int Clin Psychopharmacol 1998; 13: 229–32PubMedCrossRefGoogle Scholar
  25. 25.
    Suzuki T, Hori T, Baba A, et al. Effectiveness of anticholinergics and neuroleptic dose reduction on neuroleptic-induced pleurothotonus (the Pisa syndrome). J Clin Psychopharmacol 1999; 19: 277–80PubMedCrossRefGoogle Scholar
  26. 26.
    Kwak YT, Han I-W, Baik J, et al. Relation between cholinesterase inhibitor and Pisa syndrome [letter]. Lancet 2000; 355:2222PubMedCrossRefGoogle Scholar
  27. 27.
    Bhattacharya KF, Giannakikou I, Munroe N, et al. Primary anticholinergic-responsive Pisa syndrome. Mov Disord 2000; 15: 1285–6PubMedCrossRefGoogle Scholar
  28. 28.
    Miyaoka T, Seno H, Yamamoti C, et al. Pisa syndrome due to a cholinesterase inhibitor (donepezil): a case report. J Clin Psychiatry 2001; 62: 573–4PubMedCrossRefGoogle Scholar
  29. 29.
    Yassa R, Nastase C, Cvejic J, et al. The Pisa syndrome (or pleurothotonus): prevalence in a psychogeriatric population. Biol Psychiatry 1990; 29: 942–5CrossRefGoogle Scholar
  30. 30.
    Stubner S, Padberg F, Grohmann R, et al. Pisa syndrome (pleurothotonus): report of a multicenter drag safety surveillance project. J Clin Psychiatry 2000; 61: 569–74PubMedCrossRefGoogle Scholar
  31. 31.
    Patel S, Tariot PN, Hamill RW. Pisa syndrome without neuroleptic exposure in a patient with dementia of the Alzheimer type. J Geriatr Psychiatry Neurol 1991; 4: 48–51PubMedCrossRefGoogle Scholar
  32. 32.
    Colosimo C. Pisa syndrome in a patient with multiple system atrophy. Mov Disord 1998; 13: 607–9PubMedCrossRefGoogle Scholar
  33. 33.
    Bhatia KP, Quinn NP, Marsden CD. Clinical features and natural history of axial predominant adult onset primary dystonia. J Neurol Neurosurg Psychiatry 1997; 63: 788–91PubMedCrossRefGoogle Scholar
  34. 34.
    Fichtner CG. Pleurothotonus and the Pisa syndrome [letter]. Biol Psychiatry 1992; 31: 534PubMedCrossRefGoogle Scholar
  35. 35.
    Van Harten PR. Pisa syndrome — a confusing term. Br J Psychiatry 1992; 160: 424–5PubMedCrossRefGoogle Scholar
  36. 36.
    Wolf ME, Koller WC. Tardive dystonia: treatment with trihexyphenidyl. J Clin Psychopharmacol 1985; 5: 247–8PubMedCrossRefGoogle Scholar
  37. 37.
    Lieberman J, Lesser M, Johns C, et al. Pharmacologic studies of tardive dyskinesia. J Clin Psychopharmacol 1988; 8Suppl. 4: 57S–63SPubMedGoogle Scholar
  38. 38.
    Wojcik JD, Falk WE, Fink JS, et al. A review of 32 cases of tardive dystonia. Am J Psychiatry 1991; 148: 1055–9PubMedGoogle Scholar
  39. 39.
    Raja M. Tardive dystonia. Prevalence, risk factors, and comparison with tardive dyskinesia in a population of 200 acute psychiatric inpatients. Eur Arch Psychiatry Clin Neurosci 1995; 245: 145–51Google Scholar
  40. 40.
    Gimenez-Roldan S, Mateo D, Bartolome P. Tardive dystonia and severe tardive dyskinesia. Acta Psychiatr Scand 1985; 71:488–94PubMedCrossRefGoogle Scholar
  41. 41.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington,DC: American Psychiatric Association, 1994Google Scholar
  42. 42.
    Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989; 146: 1352–3Google Scholar
  43. 43.
    Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995; 152: 122–5PubMedGoogle Scholar
  44. 44.
    Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986; 1: 193–208PubMedCrossRefGoogle Scholar
  45. 45.
    Gardos G, Cole JO, Salomon M, et al. Clinical forms of severe tardive dyskinesia. Am J Psychiatry 1987; 144: 895–902PubMedGoogle Scholar
  46. 46.
    Yassa R, Nair NPV, Iskandar H, et al. Factors in the development of severe forms of tardive dyskinesia. Am J Psychiatry 1990; 147: 1156–63PubMedGoogle Scholar
  47. 47.
    Fahn S. Drag treatment of hyperkinetic movement disorders. Semin Neurol 1987; 7: 192–208PubMedCrossRefGoogle Scholar
  48. 48.
    Luchins DJ, Goldman M. High-dose bromocriptine in a case of tardive dystonia. Biol Psychiatry 1985; 20: 179–81PubMedCrossRefGoogle Scholar
  49. 49.
    Lamberti JS, Bellnier T. Clozapine and tardive dystonia. J Nerv Ment Dis 1993; 181: 137–8PubMedCrossRefGoogle Scholar
  50. 50.
    Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503–10PubMedCrossRefGoogle Scholar
  51. 51.
    Fahn S. High dosage anticholinergic therapy in dystonia. Neurology 1983;33:1255–61PubMedCrossRefGoogle Scholar
  52. 52.
    Yadalam KG, Korn ML, Simpson GM. Tardive dystonia: four cases histories. J Clin Psychiatry 1990; 51: 17–20PubMedGoogle Scholar
  53. 53.
    Tan CH, Tay LK. Tardive dyskinesia in elderly psychiatric patients in Singapore. Aust N Z J Psychiatry 1991;25: 119–22PubMedCrossRefGoogle Scholar
  54. 54.
    Chiu H, Shum P, Lau J, et al. Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong. Am J Psychiatry 1992; 149: 1081–5PubMedGoogle Scholar
  55. 55.
    Garver DL, Davis JM, Dekirmenjian H, et al. Dystonic reactions following neuroleptics: time course and proposed mechanisms. Psychopharmacology 1976; 47: 199–201CrossRefGoogle Scholar
  56. 56.
    Tollefson GD. Antidepressant treatment and side effect considerations. J Clin Psychiatry 1991; 52 Suppl. 5: 4–13Google Scholar
  57. 57.
    Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry 1991; 52(6 Suppl.): 4–10PubMedGoogle Scholar
  58. 58.
    Povlsen UJ, Noring U, Lund LA. Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in Cebus monkeys. Clin Neuropharmacol 1986; 9: 84–90PubMedCrossRefGoogle Scholar
  59. 59.
    Bleich A, Brown S, Kahn R. The role of serotonin in schizophrenia. Schizophr Bull 1988; 14: 297–315PubMedCrossRefGoogle Scholar
  60. 60.
    Arya DK. Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry 1994; 165: 728–33PubMedCrossRefGoogle Scholar
  61. 61.
    Casey DE. Dopaminergic and serotonergic aspects of acute extrapyramidal syndromes. Psychopharmacol Ser 1993; 10: 101–10PubMedGoogle Scholar
  62. 62.
    Friedman JH, Kucharski LT, Wagner RL. Tardive dystonia in a psychiatric hospital. J Neurol Neurosurg Psychiatry 1987; 50: 801–3PubMedCrossRefGoogle Scholar
  63. 63.
    Myslobodsky M. Pharmacologic implications of hemispheric asymmetry. Life Sci 1976; 19: 1467–78PubMedCrossRefGoogle Scholar
  64. 64.
    Oke A, Keller R, Mefford I, et al. Lateralization of norepinephrine in human thalamus. Science 1978; 200: 1411–3PubMedCrossRefGoogle Scholar
  65. 65.
    Glick SD, Ross DA, Hough LB. Lateral asymmetry of neurotransmitters in human brain. Brain Res 1982; 234: 53–63PubMedCrossRefGoogle Scholar
  66. 66.
    Tomer R, Mintz M, Myslobodsky MS. Left hemisphere hyperactivity in schizophrenia: abnormality inherent to psychosis or neuroleptic side-effects? Psychopharmacology 1982; 77: 168–70PubMedCrossRefGoogle Scholar
  67. 67.
    Reynolds GP. Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature 1983; 305: 527–9PubMedCrossRefGoogle Scholar
  68. 68.
    Farde L, Wiesel FA, Hall H, et al. No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 1987; 44: 671–2PubMedCrossRefGoogle Scholar
  69. 69.
    Arato M, Frecska E, Tekes K, et al. Serotonergic interhemispheric asymmetry: gender difference in the orbital cortex. Acta Psychiatr Scand 1991; 84: 110–1PubMedCrossRefGoogle Scholar
  70. 70.
    Martin JP. Curvature of the spine in post-encephalitic parkinsonism. J Neurol Neurosurg Psychiatry 1965; 28: 395–400PubMedCrossRefGoogle Scholar
  71. 71.
    Duvoisin RC, Marsden CD. Note on the scoliosis of parkinsonism. J Neurol Neurosurg Psychiatry 1975; 38: 787–93PubMedCrossRefGoogle Scholar
  72. 72.
    Garnett ES, Nahmias C, Firnau G. Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci 1984; 11: 174–9PubMedGoogle Scholar
  73. 73.
    Perlmutter JS, Raichle ME. Pure hemidystonia with basal ganglion abnormalities on positron emission tomography. Ann Neurol 1984; 15: 228–33PubMedCrossRefGoogle Scholar
  74. 74.
    Trabucchi M, Albizzati MG, Frattola L, et al. Hemiparkinsonism: a human model for studying dopaminergic supersensitivity. Arch Neurol 1979; 36: 246–8 Correspondence and offprints: Dr Toshihito Suzuki, Department of Psychiatry, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Department of Psychiatry, Institute of Clinical MedicineUniversity of TsukubaTsukuba, IbarakiJapan
  2. 2.Mitsukaido Kosei HospitalMitsukaido, IbarakiJapan

Personalised recommendations